Webinars Presents:

Pulmonary Arterial Hypertension (PAH): What’s New?

Monday, 11/8/2017, 7 p.m. – 8 p.m. ET

Presenter: Richard Krasuski, MD

About the Webinar
Pulmonary arterial hypertension (PAH) is a condition where the blood vessels passing to the lungs become unhealthy, resulting in an extra workload for the heart. Do you know that PAH affects up to 10% of adults with congenital heart disease (CHD) and limits their ability to exercise? It also increases their risk for hospitalization and death. Have you been told you have PAH? If you want to know more about PAH and some of the newest therapies available for its treatment, you’ll want to attend this webinar.


About the Presenter
Dr. Richard Krasuski is Director of the Adult Congenital Heart Disease Center, the Director of Hemodynamic Research, and Professor of Medicine and Pediatrics at Duke University Medical Center. Dr. Krasuski served as an officer in the United States Air Force at Wilford Hall Medical Center in Texas and then directed the Adult Congenital Heart Program at the Cleveland Clinic for a decade. He was recruited back to Duke, where he did his Cardiology Fellowship, in the summer of 2015. Dr. Krasuski currently serves on the ACHA Medical Advisory Board and is a Fellow of the American College of Cardiology (ACC), the American Heart Association (AHA) and the European Society of Cardiology (ESC).

About the Adult Congenital Heart Association
The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and promotion of ACHD research. For more information about ACHA, contact (888) 921-ACHA or visit www.achaheart.org.

This webinar is made possible in part by unrestricted educational grants from Actelion Pharmaceuticals US, Gilead Sciences, Inc., and St. Jude Medical Foundation.